本文選題：奧沙利鉑　切入點(diǎn)：紫杉醇注射液　出處：《現(xiàn)代生物醫(yī)學(xué)進(jìn)展》2016年29期 　論文類型：期刊論文

【摘要】：目的:探討奈達(dá)鉑聯(lián)合紫杉醇注射液對(duì)卵巢癌術(shù)后患者ROMA指數(shù)、HE4水平的影響及臨床療效。方法:選取我院收治的卵巢癌術(shù)后患者70例,隨機(jī)分為實(shí)驗(yàn)組和對(duì)照組,每組35例。對(duì)照組采用紫杉醇注射液治療;實(shí)驗(yàn)組在對(duì)照組基礎(chǔ)上聯(lián)合奈達(dá)鉑注射液治療。觀察并比較治療前后兩組患者ROMA指數(shù)、血清CA125和HE4水平、生存期、臨床療效及不良反應(yīng)情況。結(jié)果:與治療前相比,治療后兩組患者ROMA指數(shù)、血清CA125及HE4水平均下降,差異具有統(tǒng)計(jì)學(xué)意義(P0.05);與對(duì)照組比較,實(shí)驗(yàn)組患者治療后ROMA指數(shù)、血清HE4及CA125水平較低,差異具有統(tǒng)計(jì)學(xué)意義(P0.05);與對(duì)照組比較,實(shí)驗(yàn)組患者生存期明顯延長(zhǎng),差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:奈達(dá)鉑聯(lián)合紫杉醇注射液治療卵巢癌具有顯著的臨床療效,能夠降低ROMA指數(shù)和血清CA125、HE4水平,而且毒副作用較小,可在臨床進(jìn)一步推廣應(yīng)用。
[Abstract]:Objective: to investigate the effect of neidplatin combined with paclitaxel injection on the level of ROMA index and clinical efficacy in patients with ovarian cancer after operation. Methods: 70 patients with ovarian cancer treated in our hospital were randomly divided into experimental group and control group. 35 patients in each group were treated with paclitaxel injection in the control group, and the patients in the experimental group were treated with nedaplatin injection on the basis of the control group. The ROMA index, serum CA125 and HE4 levels, survival time of the two groups were observed and compared before and after treatment. Results: compared with before treatment, the ROMA index, serum CA125 and HE4 levels of the two groups decreased, and the difference was statistically significant (P 0.05), and compared with the control group, the ROMA index of the patients in the experimental group after treatment was lower than that in the control group. The levels of serum HE4 and CA125 were lower, the difference was statistically significant (P 0.05), compared with the control group, the survival time of the patients in the experimental group was significantly longer than that in the control group. Conclusion: nedaplatin combined with paclitaxel injection is effective in the treatment of ovarian cancer. It can reduce the ROMA index and serum CA125HE4 level, and the side effects are small, so it can be popularized in clinic.
【作者單位】： 湖北醫(yī)藥學(xué)院附屬隨州醫(yī)院婦科;
【基金】：湖北省自然科學(xué)基金項(xiàng)目(2009CDA060)
【分類號(hào)】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 崔春蕾;陶志敏;孔蕊;;紫杉醇注射液在鉑類不敏感的婦科卵巢癌中的應(yīng)用[J];中國(guó)現(xiàn)代藥物應(yīng)用;2013年12期

，

本文編號(hào)：1625365